What is amniotic fluid, its normal volume, and how are oligohydramnios and polyhydramnios evaluated and managed?

Amniotic Fluid: Definition, Normal Volume, and Management of Abnormalities

Amniotic fluid volume should be assessed using the maximum vertical pocket (MVP) method rather than the amniotic fluid index (AFI), as MVP results in fewer unnecessary interventions without compromising perinatal outcomes.

What is Amniotic Fluid?

Amniotic fluid is an integral component of the fetal environment, essential for fetal growth, lung development, and movement 1. The fluid is regulated through multiple pathways including:

• Fetal production: Fetal urine and lung fluid 1
• Fetal uptake: Swallowing and gastrointestinal absorption 1
• Intramembranous pathway: Movement across membranes 2
• Osmotic gradients: Balance of fluid movement 2

Amniotic fluid reflects both recent fetal renal perfusion and placental function, serving as a critical marker of fetal well-being 3.

Normal Amniotic Fluid Volume

Measurement Methods

Two primary ultrasound techniques are used 3:

• Maximum Vertical Pocket (MVP): Single deepest vertical pocket measured anywhere in the uterus, excluding umbilical cord or fetal parts 4
• Amniotic Fluid Index (AFI): Sum of deepest vertical pockets in four uterine quadrants 3

Normal Values

A single MVP of ≥2 cm is considered normal throughout gestation 3. For AFI, normal values vary by gestational age 3:

• At 37 weeks: AFI ≥5 cm is normal 3
• Before 37 weeks: AFI ≥8 cm is normal 3
• Alternative definition: AFI between 5th-95th percentiles for gestational age 3

Important caveat: The volume of fluid per centimeter of AFI changes dramatically during pregnancy—increasing 61% from 20 to 30 weeks, then decreasing 14.7% from 30 to 34 weeks 5. This means the same AFI measurement represents vastly different actual fluid volumes at different gestational ages.

Oligohydramnios: Evaluation and Management

Definition

Oligohydramnios is defined as MVP <2 cm or AFI <5 cm 3. However, MVP is the preferred diagnostic method because AFI leads to overdiagnosis, resulting in more obstetric interventions without improving perinatal outcomes 3, 6, 2.

Clinical Significance

Oligohydramnios is independently associated with stillbirth (OR 2.6,95% CI 2.1-3.2) in large retrospective studies 3. However, isolated oligohydramnios at term shows conflicting evidence—one meta-analysis found no differences in meconium, Apgar scores, pH, NICU admission, or perinatal deaths 3, while other studies support stillbirth rates of 1-2% 3.

Evaluation Algorithm

When oligohydramnios is identified 1:

1. Exclude premature preterm rupture of membranes clinically 1
2. Assess fetal growth: Evaluate for fetal growth restriction 1
3. Evaluate genitourinary system for:
   • Renal agenesis 1
   • Multicystic dysplastic kidneys 1
   • Ureteropelvic junction obstruction 1
   • Bladder outlet obstruction 1
4. Perform detailed fetal anatomic survey 1
5. Correlate with maternal conditions 1

Management

For isolated oligohydramnios, initiate antenatal testing given the association with stillbirth 3. The ACR guidelines support current practice of antenatal testing in patients with low fluid 3.

For oligohydramnios with fetal growth restriction: Consider delivery at 34 0/7 to 37 6/7 weeks of gestation 7.

Critical pitfall: While oligohydramnios assessment can inform overall fetal well-being, it should not be used to determine management in isolation 6. Umbilical artery Doppler remains the primary surveillance tool 6.

Polyhydramnios: Evaluation and Management

Definition

Polyhydramnios is defined as MVP >8 cm or AFI ≥24 cm (or >95th percentile for gestational age) 3, 8.

Clinical Significance

Polyhydramnios is a significant independent risk factor for adverse outcomes 3:

• Perinatal mortality: OR 5.8 (95% CI 3.68-9.11) in one study 3
• Fetal demise: OR 5.5 (95% CI 4.1-7.6) in nonanomalous singleton pregnancies 3
• Stillbirth: OR 1.8 (95% CI 1.4-2.2) in large retrospective study 3

Isolated polyhydramnios has lower perinatal mortality than cases with additional fetal abnormalities 3.

Evaluation Algorithm

When polyhydramnios is identified 8:

1. Screen for maternal diabetes mellitus (most common pathologic cause) 8
2. Perform detailed fetal anatomic survey evaluating for:
   • Gastrointestinal obstruction: Esophageal atresia, duodenal atresia 1
   • Oropharyngeal or thoracic masses 1
   • Neurologic anomalies: Affecting swallowing 1
   • Musculoskeletal anomalies 1
3. Consider genetic evaluation: Especially if fetal anomalies present 8
4. Evaluate for congenital infection 8
5. Assess for alloimmunization 8

Most cases of mild polyhydramnios are idiopathic 8.

Management

Amnioreduction should be considered ONLY for severe maternal discomfort or dyspnea in the setting of severe polyhydramnios 8. It is performed solely for maternal indications, not to improve fetal outcomes 1.

Indomethacin should NOT be used for the sole purpose of decreasing amniotic fluid 8. While NSAIDs may reduce polyhydramnios, they carry significant fetal risks including ductus arteriosus constriction, requiring fetal echocardiography monitoring 9.

For mild idiopathic polyhydramnios: Antenatal fetal surveillance is not required 8. Labor should occur spontaneously at term, with induction not before 39 weeks absent other indications 8.

For severe polyhydramnios: Deliver at a tertiary center due to significant possibility of fetal anomalies 8.

Special Consideration: Paradoxical Polyhydramnios with Growth Restriction

Polyhydramnios with fetal growth restriction is paradoxical and warrants specific evaluation 1:

• If maternal diabetes or hypertension present, these explain the combination 1
• When these maternal conditions are absent, this raises concern for aneuploidy 1

Surveillance in High-Risk Pregnancies

Amniotic fluid assessment is an essential component of fetal surveillance 3:

• In modified biophysical profile (mBPP): Assessed as AFI 3
• In biophysical profile (BPP): Assessed as MVP 3

Normal amniotic fluid is reassuring, with likelihood of stillbirth within 1 week of normal mBPP or BPP <1 in 1,000 3.